Appendix 3Y
Change of Director
’
s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director
’
s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX
’
s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
NOVOGEN LIMITED
ABN
37 063 259 754
We
(the
entity)
give
ASX
the
following
information
under
listing
rule
3.19A.2
and
as
agent
for
the director for the purposes of section 205G of the Corporations
Act.
Name of Director
Robert Howard Birch
Date of last notice
14 December 2012
Part 1 - Change of director
’
s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of
“
notifiable interest of a director
”
should
be disclosed in this part.
Direct or indirect interest
Direct
Indirect
–
Aquagolf Pty Limited <Aquagolf
Pty Ltd Superannuation Fund A/c>
Nature of indirect interest
(including registered holder)
Controlled entity
Note:
Provide
details
of
the
circumstances
giving
rise
to
the
relevant
interest.
Date of change
13 February 2013
No. of securities held prior to change
Direct
36,750 Ordinary Shares
Aquagolf
Pty
Limited
<Aquagolf
Pty
Ltd S/F A/c>
1,100,000 Ordinary Shares
Class
Ordinary Shares
Number acquired
397,136
Number disposed
Nil
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y
Change of Director
’
s Interest Notice
Value/Consideration
As
part
of
consideration
for shares
held in
Note:
If
consideration is non-cash, provide
details and estimated
valuation
Triaxial Pharmaceuticals
P/L
No. of securities held after change
Direct
36,750 Ordinary Shares
Aquagolf
Pty
Limited
<Aquagolf
Pty
Ltd S/F A/c>
1,497,136 Ordinary Shares
Nature of change
As
part
of
consideration
for
shares
in
Example:
on-market
trade,
off-market
trade,
exercise
of
options,
issue
of
securities
under
dividend
reinvestment
plan,
participation
in
Triaxial Pharmaceuticals
P/L
buy-back
Part 2
–
Change of director
’
s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of
“
notifiable interest of a director
”
should
be disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
N/A
(if issued securities)
Date of change
N/A
No.
and
class
of
securities
to
which
N/A
interest related prior to change
Note:
Details
are
only
required
for
a
contract
in
relation to which the interest has changed
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director
’
s Interest Notice
Part 3
–
+
Closed period
Were
the
interests
in
the
securities
or
contracts
detailed
No
–
consideration for share
above traded during a
+
closed period where prior written
purchase agreement dated 7
clearance was required?
December 2012
If
so,
was
prior
written
clearance
provided
to
allow
the
trade
N/A
to proceed during this period?
If prior written clearance was provided, on what date was this
N/A
provided?
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 3
Appendix 3Y
Change of Director
’
s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director
’
s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX
’
s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
NOVOGEN LIMITED
ABN
37 063 259 754
We
(the
entity)
give
ASX
the
following
information
under
listing
rule
3.19A.2
and
as
agent
for
the director for the purposes of section 205G of the Corporations
Act.
Name of Director
Andrew Heaton
Date of last notice
13 December 2012
Part 1 - Change of director
’
s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of
“
notifiable interest of a director
”
should
be disclosed in this part.
Direct or indirect interest
Direct
Nature of indirect interest
(including registered holder)
Note:
Provide
details
of
the
circumstances
giving
rise
to
the
relevant
interest.
Date of change
13 February 2013
No. of securities held prior to change
28,344 Ordinary Shares
Class
Ordinary Shares
Number acquired
7,572,056
Number disposed
Nil
Value/Consideration
As
part
of
consideration
for shares held in
Note:
If
consideration is non-cash, provide details and estimated
valuation
Triaxial Pharmaceuticals
P/L
No. of securities held after change
7,600,400 Ordinary Shares
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y
Change of Director
’
s Interest Notice
Nature of change
As
part
of
consideration
for
shares
in
Example:
on-market
trade,
off-market
trade,
exercise
of
options,
issue
of
securities
under
dividend
reinvestment
plan,
participation
in
Triaxial Pharmaceuticals
P/L
buy-back
Part 2
–
Change of director
’
s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of
“
notifiable interest of a director
”
should
be disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
N/A
(if issued securities)
Date of change
N/A
No.
and
class
of
securities
to
which
N/A
interest related prior to change
Note:
Details
are
only
required
for
a
contract
in
relation to which the interest has changed
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
N/A
Part 3
–
+
Closed period
Were
the
interests
in
the
securities
or
contracts
detailed
No
–
consideration for share
above traded during a
+
closed period where prior written
purchase agreement dated 7
clearance was required?
December 2012
If
so,
was
prior
written
clearance
provided
to
allow
the
trade
N/A
to proceed during this period?
If prior written clearance was provided, on what date was this
N/A
provided?
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director
’
s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director
’
s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX
’
s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
NOVOGEN LIMITED
ABN
37 063 259 754
We
(the
entity)
give
ASX
the
following
information
under
listing
rule
3.19A.2
and
as
agent
for
the director for the purposes of section 205G of the Corporations
Act.
Name of Director
Graham Kelly
Date of last notice
13 December 2012
Part 1 - Change of director
’
s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of
“
notifiable interest of a director
”
should
be disclosed in this part.
Direct or indirect interest
Indirect
Nature of indirect interest
1.
Bende Holdings Pty Ltd
–
controlled
(including registered holder)
entity
Note:
Provide
details
of
the
circumstances
giving
rise
to
the
relevant
interest.
2.
Coolawin Rd Pty Ltd
–
controlled entity
3.
Coolawin Rd Super Fund
–
controlled
entity
4.
Phytose Corporation Pty Ltd
–
controlled entity
Date of change
13 February 2013
No. of securities held prior to change
1.
Bende Holdings Pty Ltd
1,677,343 ordinary shares
2.
Coolawin Rd Pty Ltd
503,300 ordinary shares
3.
Coolawin Rd Super Fund
10,354 ordinary shares
4.
Phytose Corporation Pty Ltd
Nil
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y
Change of Director
’
s Interest Notice
Class
Ordinary Shares
Number acquired
Phytose Corporation Pty Ltd
1,694,795 ordinary shares
Number disposed
Nil
Value/Consideration
As
part
of
consideration
for shares held in
Note:
If
consideration is non-cash, provide details and estimated
valuation
Triaxial Pharmaceuticals
P/L
No. of securities held after change
1.
Bende Holdings Pty Ltd
1,677,343 ordinary shares
2.
Coolawin Rd Pty Ltd
503,300 ordinary shares
3.
Coolawin Rd Super Fund
10,354 ordinary shares
4.
Phytose Corporation Pty Ltd
1,694,795 ordinary shares
Nature of change
As
part
of
consideration
for
shares
in
Example:
on-market
trade,
off-market
trade,
exercise
of
options,
issue
of
securities
under
dividend
reinvestment
plan,
participation
in
Triaxial Pharmaceuticals
P/L
buy-back
Part 2
–
Change of director
’
s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of
“
notifiable interest of a director
”
should
be disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
N/A
(if issued securities)
Date of change
N/A
No.
and
class
of
securities
to
which
N/A
interest related prior to change
Note:
Details
are
only
required
for
a
contract
in
relation to which the interest has changed
Interest acquired
N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director
’
s Interest Notice
Interest disposed
N/A
Value/Consideration
N/A
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
N/A
Part 3
–
+
Closed period
Were
the
interests
in
the
securities
or
contracts
detailed
No
–
consideration for share
above traded during a
+
closed period where prior written
purchase agreement dated 7
clearance was required?
December 2012
If
so,
was
prior
written
clearance
provided
to
allow
the
trade
N/A
to proceed during this period?
If prior written clearance was provided, on what date was this
N/A
provided?
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 3
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024
